Positive data for Alecensa in lung cancer - Roche



A Phase 3 trial of the kinase inhibitor Alecensa (alectinib) has shown a statistically significant improvement in disease-free survival in patients with early-stage anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, Roche reported on 1 September. Alecensa is already approved for advanced ALK-positive lung cancer. The latest data have now shown effectiveness in an early disease setting as well. ALC-positive lung cancer is a molecular subset of non-small cell lung cancer with distinct pathological features.